Magnetic resonance imaging with restriction spectrum imaging may help clinicians better identify prostate cancer staging.
Enhanced MRI diffusion with restriction spectrum imaging (RSI-MRI) shows promise for substantially improving prostate cancer imaging, according to a study published in the journal Prostate Cancer and Prostatic Disease.
Researchers from the University of California, San Diego School of Medicine, and the University of California, Los Angeles, developed a novel, enhanced MRI diffusion technique using restriction spectrum imaging and compared its efficacy with standard MRI for detecting extraprostatic extension (EPE).
Twenty-seven patients with prostate cancer who underwent MRI and RSI-MRI prior to radical prostatectomy were evaluated. Ten patients had histologically proven pT3 disease.[[{"type":"media","view_mode":"media_crop","fid":"30855","attributes":{"alt":"Rebecca Rakow-Penner, MD, PhD","class":"media-image media-image-right","id":"media_crop_6210645127716","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3242","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"Rebecca Rakow-Penner, MD, PhD","typeof":"foaf:Image"}}]]
The results showed that the standard preoperative MRI correctly identified extraprostatic extension in two patients (22%) of the nine with pT2. The RSI-MRI identified EPE in eight of the nine patients (89%), and the technique also correctly identified pT2 disease in the remaining 18 patients.
"This new approach is a more reliable imaging technique for localizing tumors. It provides a better target for biopsies, especially for smaller tumors," first author Rebecca Rakow-Penner, MD, PhD, research resident in the Department of Radiology, University of California San Diego, said in a release.
The researchers concluded that although more research is needed, their RSI-MRI technology was feasible and showed promise in imaging for prostate cancer.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
Can AI Automate BPE Assessment of Dense Breasts on MRI?
April 3rd 2024An MRI-based machine learning model demonstrated a comparable background parenchymal enhancement (BPE) hazard ratio to that of manual BPE assessment for breast cancer, according to a study of over 4,500 women with dense breasts.
Are Prostate Biopsies Necessary in Patients with Negative or Equivocal MRIs and Low PSA Density?
April 2nd 2024Up to 48 percent of unnecessary prostate biopsies could be eliminated by limiting biopsy to patients with PI-RADS 4 and higher MRI assessments and a prostate-specific antigen density level below 0.15 ng/mL2, according to a new meta-analysis.